Bills · 2017-2018 Regular Session
Relating to: prescription drug cost reporting by manufacturers and providing a penalty. (FE)
Drugs Health services, department of — Administration Insurance — Commissioner, office of
- Introduced, stopped here
- Passes Assembly, not reached
- Passes Senate, not reached
- Governor signs, not reached
- Law, not reached
Unfamiliar terms? Glossary
What this bill does
Plain-language analysis by the nonpartisan Legislative Reference Bureau
This bill requires certain cost reporting by manufacturers of brand-name and
generic drugs. The bill requires a manufacturer to notify the Department of Health
Services and the Office of the Commissioner of Insurance if it is 1) increasing the
wholesale acquisition cost of a brand-name drug on the market in Wisconsin by more
than 25 percent over a 24-month period; 2) intending to introduce in Wisconsin a
brand-name drug that has an annual wholesale acquisition cost of $30,000 or more;
3) increasing the wholesale acquisition cost of a generic drug on the market in
Wisconsin by more than 25 percent or by more than $300 during any 12-month
period; or 4) intending to introduce in Wisconsin a generic drug that has an annual
wholesale acquisition cost of $3,000 or more. The manufacturer must provide the
notice at least 30 days before the planned date of the increase or introduction and
must provide a justification including a description described in the bill. A
manufacturer is also required to report annually to DHS and OCI the value of price
concessions provided to each pharmacy benefit manager for each drug sold in
Wisconsin for which a notice was required. The bill also requires each manufacturer
of a brand-name or generic drug sold in Wisconsin to submit to DHS and OCI a report
containing a description of each manufacturer-sponsored assistance program in
effect during the previous year that includes the criteria for participation, program
terms, and the number of prescriptions and the total market value of assistance
provided to residents of Wisconsin under the program. The manufacturer must
certify the information provided in a notice or report required under the bill under
penalty of perjury, and failure to provide the notice or report is subject to a forfeiture
determined by DHS but not to exceed $10,000 per day past due.
The bill requires DHS to publish the pricing justification information reported
by manufacturers on its Internet site. DHS must also analyze the information and
publish a report on its Internet site describing trends in drug pricing.
Sponsors
Introduced by: Anderson (D) , Berceau (D) , Billings (D) , Brostoff (D) , Considine (D) , Crowley (D) , Genrich (D) , Hebl (D) , Hesselbein (D) , Hintz (D) , Kolste (D) , Ohnstad (D) , Pope (D) , Riemer (D) , Sargent (D) , Shankland (D) , Sinicki (D) , Spreitzer (D) , Subeck (D) , Vruwink (D) , Young (D) , Zamarripa (D) , Zepnick (D)
1 cosponsors
Erpenbach (D)
Votes
Suspending the rules (to take a vote immediately) needs a two-thirds majority — a higher bar than passing the bill, which needs a simple majority. That's why a suspension motion can show more Ayes than the passage vote that follows it. Glossary
Assembly: Refused to suspend rules to withdraw from committee on Health and take up, Ayes 34, Noes 59
Failed 34–59 Feb 22, 2018 official source full pageNo individual roll call was recorded for this vote. Committee votes and some older sessions record totals only.
Full history
- Nov 9, 2017 · Assembly
Introduced by Representatives Kolste, Spreitzer, Sargent, Zamarripa, Genrich, Anderson, Berceau, Pope, Subeck, Considine, Billings, Brostoff, Hesselbein, Vruwink, Ohnstad, Hintz, Young, Shankland, Zepnick, Riemer, Crowley, Hebl and Sinicki; cosponsored by Senator Erpenbach
- Nov 9, 2017 · Assembly
Read first time and referred to Committee on Health
- Feb 22, 2018 · Assembly
Refused to suspend rules to withdraw from committee on Health and take up, Ayes 34, Noes 59
- Mar 28, 2018 · Assembly
Failed to pass pursuant to Senate Joint Resolution 1